Page 7273: in Table 1 under “Survivors N = 204,” in the row “Diagnosed with second malignancy,” the value should read “48 (24.0),” not “51 (25.0).” The corrected Table 1 is shown below:
Table 1.
Characteristics of survivors of HL and community controls
| . | Survivors N = 204 . | Controls N = 205 . | P value . |
|---|---|---|---|
| n (%) . | n (%) . | ||
| Sex | |||
| Male | 97 (47.5) | 99 (48.3) | 0.88 |
| Female | 107 (52.5) | 106 (51.7) | |
| Race | |||
| White | 172 (84.3) | 176 (85.9) | 0.66 |
| Other | 32 (15.7) | 29 (14.1) | |
| Smoking Status | |||
| Current | 39 (19.1) | 29 (14.3) | 0.37 |
| Former | 35 (17.2) | 41 (20.2) | |
| Never | 130 (63.7) | 133 (65.5) | |
| Body mass index | |||
| Underweight | 7 (3.4) | 3 (1.5) | 0.23 |
| Normal weight | 51 (25.0) | 62 (30.2) | |
| Overweight | 73 (35.8) | 60 (29.3) | |
| Obese | 73 (35.8) | 80 (39.0) | |
| Age at assessment (y) | Mean (SD) | ||
| 36.6 (8.01) | 36.7 (9.17) | 0.84 | |
| Median (min-max) | |||
| Age at diagnosis (y) | 14.7 (3.0-22.6) | ||
| Time since diagnosis (y) | 20.6 (10.7-45.6) | ||
| Anthracyclines (n = 156) mg/m2 | 157.2 (91.0-400.0)∗ | ||
| IV methotrexate (n = 85) mg/m2 | 123.2 (20.3-167.7) | ||
| Bleomycin (n = 58) mg/m2 | 35.6 (5.0-95.0) | ||
| Corticosteroids (n = 140) mg/m2 | 2240 (250-4480) | ||
| Vincristine (n=182) mg/m2 | 45.9 (9.2-151.2) | ||
| Cyclophosphamides (n=113) mg/m2 | 3655 (1332-22 889)† | ||
| Chest Radiation (n=204) Gy | 26.0 (15.0-45.0) | ||
| Neck Radiation (n=204) Gy | 26.0 (15.0-51.0) | ||
| N (%) | |||
| Relapsed | 14 (6.9) | ||
| Diagnosed with second malignancy | 48 (24.0) |
| . | Survivors N = 204 . | Controls N = 205 . | P value . |
|---|---|---|---|
| n (%) . | n (%) . | ||
| Sex | |||
| Male | 97 (47.5) | 99 (48.3) | 0.88 |
| Female | 107 (52.5) | 106 (51.7) | |
| Race | |||
| White | 172 (84.3) | 176 (85.9) | 0.66 |
| Other | 32 (15.7) | 29 (14.1) | |
| Smoking Status | |||
| Current | 39 (19.1) | 29 (14.3) | 0.37 |
| Former | 35 (17.2) | 41 (20.2) | |
| Never | 130 (63.7) | 133 (65.5) | |
| Body mass index | |||
| Underweight | 7 (3.4) | 3 (1.5) | 0.23 |
| Normal weight | 51 (25.0) | 62 (30.2) | |
| Overweight | 73 (35.8) | 60 (29.3) | |
| Obese | 73 (35.8) | 80 (39.0) | |
| Age at assessment (y) | Mean (SD) | ||
| 36.6 (8.01) | 36.7 (9.17) | 0.84 | |
| Median (min-max) | |||
| Age at diagnosis (y) | 14.7 (3.0-22.6) | ||
| Time since diagnosis (y) | 20.6 (10.7-45.6) | ||
| Anthracyclines (n = 156) mg/m2 | 157.2 (91.0-400.0)∗ | ||
| IV methotrexate (n = 85) mg/m2 | 123.2 (20.3-167.7) | ||
| Bleomycin (n = 58) mg/m2 | 35.6 (5.0-95.0) | ||
| Corticosteroids (n = 140) mg/m2 | 2240 (250-4480) | ||
| Vincristine (n=182) mg/m2 | 45.9 (9.2-151.2) | ||
| Cyclophosphamides (n=113) mg/m2 | 3655 (1332-22 889)† | ||
| Chest Radiation (n=204) Gy | 26.0 (15.0-45.0) | ||
| Neck Radiation (n=204) Gy | 26.0 (15.0-51.0) | ||
| N (%) | |||
| Relapsed | 14 (6.9) | ||
| Diagnosed with second malignancy | 48 (24.0) |
Max, maximum; min, minimum; SD, standard deviation.
∗
Anthracycline equivalent dose.
†
Cyclophosphamide equivalent dose.
Page 7274: in Table 2 under the “Survivors Mean (SD)” and “Controls Mean (SD)” columns, the authors misreported the means and standard deviations of the neurocognitive test at the hundredth decimal place. The corrected Table 2 is shown below:
Table 2.
Mean age-adjusted neurocognitive z scores of survivors and controls
| Domain . | Survivors . | Controls . | FDR P . |
|---|---|---|---|
| Mean (SD) . | Mean (SD) . | ||
| Attention | |||
| Focused | 0.35 (0.95) | 0.54 (0.84) | 0.061 |
| Span | 0.04 (1.01) | 0.22 (0.92) | 0.085 |
| Sustained | -0.10 (1.35) | 0.23 (0.89) | 0.011 |
| Variability | -0.23 (1.11) | -0.03 (1.05) | 0.089 |
| Processing Speed | |||
| Reaction time | -0.16 (1.17) | -0.04 (0.99) | 0.29 |
| Visuomotor | 0.13 (0.96) | 0.40 (0.94) | 0.011 |
| Visual | 0.27 (0.98) | 0.62 (0.97) | 0.002 |
| Motor | -0.38 (1.05) | -0.01 (0.90) | 0.001 |
| Memory | |||
| Verbal learning | -0.08 (1.04) | 0.31 (1.02) | 0.001 |
| Short-term recall | -0.24 (1.01) | 0.12 (1.04) | 0.002 |
| Long-term recall | -0.30 (1.14) | 0.08 (1.10) | 0.002 |
| Selective reminding | -0.18 (1.11) | -0.03 (0.96) | 0.17 |
| Executive Function | |||
| Working memory | -0.08 (0.93) | 0.05 (0.86) | 0.16 |
| Self-monitoring | -0.00 (1.14) | 0.20 (0.95) | 0.085 |
| Cognitive flexibility | -0.02 (1.26) | 0.26 (1.11) | 0.033 |
| Fluency | -0.05 (1.20) | 0.03 (1.05) | 0.47 |
| Domain . | Survivors . | Controls . | FDR P . |
|---|---|---|---|
| Mean (SD) . | Mean (SD) . | ||
| Attention | |||
| Focused | 0.35 (0.95) | 0.54 (0.84) | 0.061 |
| Span | 0.04 (1.01) | 0.22 (0.92) | 0.085 |
| Sustained | -0.10 (1.35) | 0.23 (0.89) | 0.011 |
| Variability | -0.23 (1.11) | -0.03 (1.05) | 0.089 |
| Processing Speed | |||
| Reaction time | -0.16 (1.17) | -0.04 (0.99) | 0.29 |
| Visuomotor | 0.13 (0.96) | 0.40 (0.94) | 0.011 |
| Visual | 0.27 (0.98) | 0.62 (0.97) | 0.002 |
| Motor | -0.38 (1.05) | -0.01 (0.90) | 0.001 |
| Memory | |||
| Verbal learning | -0.08 (1.04) | 0.31 (1.02) | 0.001 |
| Short-term recall | -0.24 (1.01) | 0.12 (1.04) | 0.002 |
| Long-term recall | -0.30 (1.14) | 0.08 (1.10) | 0.002 |
| Selective reminding | -0.18 (1.11) | -0.03 (0.96) | 0.17 |
| Executive Function | |||
| Working memory | -0.08 (0.93) | 0.05 (0.86) | 0.16 |
| Self-monitoring | -0.00 (1.14) | 0.20 (0.95) | 0.085 |
| Cognitive flexibility | -0.02 (1.26) | 0.26 (1.11) | 0.033 |
| Fluency | -0.05 (1.20) | 0.03 (1.05) | 0.47 |
Means and SDs presented as age-adjusted z scores, with population mean = 0 and SD = 1.0.
FDR, P, false discovery rate–adjusted P-values for multiple comparisons between survivors and control; SD, standard deviation.
These errors do not impact the P values, statistical significance, or relevant interpretations of the data.
© 2024 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.
2024
